Skip to main navigation Skip to search Skip to main content

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)

  • M Raikou
  • , A McGuire
  • , H M Colhoun
  • , D J Betteridge
  • , P N Durrington
  • , G A Hitman
  • , H A W Neil
  • , S J Livingstone
  • , V Charlton-Menys
  • , J H Fuller
  • , CARDS Investigators

    Research output: Contribution to journalArticlepeer-review

    Abstract

    We estimated the cost-effectiveness of atorvastatin treatment in the primary prevention of cardiovascular disease in patients with type 2 diabetes using data from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Original languageEnglish
    Pages (from-to)733-740
    Number of pages8
    JournalDiabetologia
    Volume50
    Issue number4
    DOIs
    Publication statusPublished - 2007

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)'. Together they form a unique fingerprint.

    Cite this